ArticleFrontiers in medicine2025
Mixed-type autoimmune hemolytic anaemia complicated by acute cerebral infarction: a case report.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In patients with autoimmune hemolytic anaemia (AIHA), numerous factors can influence disease severity, and thrombotic complications are associated with increased morbidity and mortality. Reports of autoimmune hemolytic anemia complicated by acute cerebral infarction are relatively rare. Case presentation: We report a case of an 82-year-old female patient with hypertension who developed mixed-type AIHA complicated by acute cerebral infarction following intravenous infusion of ceftriaxone after erysipelas in which the patient's previous hemoglobin (Hb) level was maintained at approximately 108 g/L. After developing erysipelas and treatment with ceftriaxone, the patient experienced a continuous decline in Hb, hematocrit (HT), and red blood cell (RBC) counts. Direct antiglobulin test (DAT) was positive for IgG and C3d, and both the reticulocyte count and proportion were elevated. The treatment regimen included methylprednisolone, enoxaparin for anticoagulation, and clopidogrel for antiplatelet aggregation. Following targeted treatment, the patient's condition improved. Conclusion: Clinicians should be aware of the potential contributing factors in patients with mixed-type AIHA who develop neurological deficits due to severe anemia. This case report aims to emphasize the laboratory aspects of mixed-type AIHA and the necessity for clinicians to recognize the potentially fatal consequences of acute thromboembolism in mixed-type AIHA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.